Tn Antigen: Peter Mac Interim Development Clinical Study Results -- MEDICA - World Forum for Medicine

19/04/2022

Universal Biosensors Pty. Ltd.

Tn Antigen: Peter Mac Interim Development Clinical Study Results

Universal Biosensors, Inc. (ASX:UBI) is pleased to announce interim results from the Peter Mac sponsored Tn Antigen1 “Development Clinical Study” (initially announced on 14 September 2021).
UBI is developing a handheld portable Tn Antigen cancer biosensor using a “finger prick” blood test to accurately measure changes to a cancer patient’s tumor status (monitoring of remission and reoccurrence) delivering easier, cheaper, and more frequent tests. The Tn Antigen biosensor test could be used by oncologists and cancer patients in clinics, hospitals, GP clinics or at home.

Exhibitor Data Sheet